A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

Over the past few years, a new class of injectable medications has changed the way obesity is treated. Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight ...

As the Food and Drug Administration clamps down on off-brand weight loss medications, Seattle-area residents are stocking up ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

A major 72-week trial shows tirzepatide leads to double-digit weight loss and greater waist reduction than semaglutide, reshaping obesity treatment strategies and offering new hope for patients ...

The FDA has been cut off from producing compounded weight-loss drugs such as Ozempic, Mounjaro or Wegovy, the most effective ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

GLP-1 stands for glucagon-like peptide-1, a satiety hormone the body produces when we eat to help stimulate digestion and ...

Compounded GLP-1s are no longer to be sold following the FDA announcement that the shortage of semaglutide and tirzepatide ended.

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.